Table 2.
m/z | Avg LOD [ng/ml, (pg/injection),n=5] |
||||
---|---|---|---|---|---|
d3 labeled | non- d3 labeled | ||||
Peak number | Derivatized estrogens | Linearity * | |||
1 | 16-epiestriol | 411.2911 | 408.2675 | y = 0.9901x + 0.032; r2 = 0.9925 | 2.34 (11.71) |
2 | 16-keto-17β-estradiol | 409.2611 | 406.2359 | y = 0.9243x + 0.013; r2 = 0.9953 | 0.39 (1.99) |
3 | 16α-hydroxyestrone | 409.2714 | 406.2373 | y = 1.1043x + 0.010; r2 = 0.9989 | 0.62 (3.12) |
4 | estriol | 411.2944 | 408.2596 | y = 0.8445x + 0.052; r2 = 0.9969 | 0.69 (3.47) |
5 | 17-epiestriol | 411.2924 | 408.2642 | y = 0.8582x + 0.044; r2 = 0.9957 | 0.46 (2.34) |
6 | 4-hydroxyestradiol | 411.2786 | 408.255 | y = 0.8376x + 0.047; r2 = 0.9952 | 0.75 (3.75) |
7 | 4-hydroxyestrone | 409.2586 | 406.2433 | y = 0.8411x + 0.060; r2 = 0.9885 | 0.56 (2.84) |
8 | 2-hydroxyestradiol | 411.2882 | 408.258 | y = 1.1139x + 0.019; r2 = 0.9966 | 0.69 (3.47) |
9 | 2-hydroxyestrone | 409.2812 | 406.2363 | y = 0.8512x + 0.054; r2 = 0.9989 | 0.75 (3.75) |
10 | 17β-estradiol | 395.2286 | 392.1844 | y = 0.8421x + 0.016; r2 = 0.9988 | 0.44 (2.23) |
11 | 4-methoxyestradiol | 425.3775 | 422.3347 | y = 0.8921x + 0.033; r2 = 0.9987 | 0.48 (2.40) |
12 | 2-methoxyestradiol | 425.3782 | 422.3412 | y = 0.8656x + 0.041; r2 = 0.9988 | 0.37 (1.87) |
13 | estrone | 393.2098 | 390.1731 | y = 0.8797x + 0.039; r2 = 0.9928 | 0.36 (1.80) |
14 | 4-methoxyestrone | 423.3415 | 420.3153 | y = 0.8856x + 0.027; r2 = 0.9986 | 0.62 (3.12) |
15 | 2-methoxyestrone | 423.3394 | 420.3125 | y = 0.8934x + 0.021; r2 = 0.9980 | 0.46 (2.34) |
16 | 2-hydroxyestrone-3-methyl ether | 423.3481 | 420.315 | y = 0.9089x + 0.029; r2 = 0.9989 | 0.62 (3.12) |
x= Concentration ratio of non-d3 labeled to d3-labeled analytes; y= average extracted ion chromatographic peak intensity ratio of these pair of analytes. Linearity range for all is 1:1~1:40.